Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Refix ceiling price of ...

    Refix ceiling price of Zydus Healthcare Tiotropium Inhalation: DoP directs NPPA

    Meghna A SinghaniaWritten by Meghna A Singhania Published On 2019-06-23T16:57:35+05:30  |  Updated On 2021-08-16T10:31:21+05:30

    New Delhi: Allowing the review petition of Zydus Healthcare Limited regarding price fixation of Tiotropium Inhalation (MDI) 9 mcg/dose, the Department of Pharmaceuticals (DoP) has directed National Pharmaceutical Pricing Authority (NPPA) to refix ceiling price of the said formulation.


    The formulation is used to control and prevent symptoms of respiratory diseases such as asthma and chronic obstructive pulmonary disease. Tiotropium is also sold by drugmakers including Cipla, Glenmark Pharma, Lupin and Macleods Pharma


    In its decision, DoP ordered NPPA to refix the ceiling prices of Tiotropium Inhalation (MDI) 9mcg/dose by considering the Price to Retailer (PTR) of Tiomist 9mcg MDI being manufactured and marketed by Cadila Healthcare Limited for the month of August, 2015, in addition to the data of other Metered Dose Inhalation(MDI) manufacturing companies.


    Zydus in its plea contended that NPPA has made available the working sheet towards the ceiling price of the said formulation only on 12.3.2019. While going through the working sheet, it was observed that the brand Tiomist HFA 9mcg inhaler manufactured by Cadila Healthcare Limited (CHL), Zydus Cadila Group, does not feature at all. As on August 2015, CHL was manufacturing and marketing the said brand in India.


    Cadila had filed a scheme of arrangement for transfer of the India Human Formulation Undertaking to its wholly owned subsidiary Zydus Healthcare with National Company Law Tribunal (NCLT) Bench at Ahmedabad, on a going concern basis, by way of slump sale. NCLT had passed an order in the matter of scheme of arrangement for transfer of the Indian Human Formulation Undertaking to Zydus Healthcare Limited on 18.5.2017. NPPA was informed about the said NCLT order.


    Zydus further stated that Tiomist HFA 9mcg Inhaler was manufactured and marketed by CHL, Zydus Cadila as of August 2015. The product is manufactured and marketed by ZHL, Zydus Cadila w.e.f. 18.5.17. The AWACS data of August 2015 shows that Tiomist HFA 9mcg Inhaler of Zydus Cadila has MRP of Rs. 400.31, PTR of 311.29, MAT Value of 1.35 as of August 2015 and a Market share of 6%.


    However, NPPA in its working sheet made available on 12.3.2019 has not considered the said brand having a market share of 6%. It should have been considered because CHL, Zydus Cadila was manufacturing and marketing the said brand in August 2015. While this is also a fact that the said brand is now being manufactured and marketed by ZHL, Zydus Cadila and features in the latest AWACS data.


    The company thus sought to direct NPPA to correct the ceiling price of Tiotropium Inhalation (MDI) 9mcg/dose after considering the correct PTR of brand Tiomist HFA 9mcg Inhaler.


    In response to the contentions, NPPA said that NPPA has notified the revised ceiling price considering the data submitted by the concerned companies. Zydus was informed about the same stating that the company did not submit the data with respect to Tiomist 9mcg MDI. Accordingly, NPPA has considered the data submitted by the concerned companies.


    Deliberating the matter, DoP observed that NPPA fixed the ceiling price of the formulation by considering the data collected from Metered Dose Inhalation (MDI) manufacturing companies for the month of August 2015, and considered the data of four companies, viz. Cipla Ltd., Glenmark Pharmaceuticals Ltd., Lupin Ltd. and Macleods Pharmaceuticals Pvt. Ltd. NPPA did not consider the data in respect of product Tiomist 9mcg MDI on the ground that Zydus has not submitted the data with respect to the said product.




    The company started the manufacturing and marketing of Tiomist 9mcg MDI after passing an order in the matter of scheme of arrangement for transfer of the Indian Human Formulation Undertaking to the company by NCLT. Till then, the said product was being manufactured and marketed by Cadila Healthcare Limited (CHL). It means, the data of the said product for the month of August 2015 was available with CHL and not with ZHL. The market share of CHL was 6% in the month of August 2015. Zydus submitted documentary proof in support of its claim.



    In view of the above, DoP held that NPPA needs to refix the ceiling price of Tiotropium Inhalation (MDI) 9mcg/dose by also considering the PTR of Tiomist 9mcg MDI being manufactured and marketed by M/s Cadila Healthcare Limited for the month of August 2015, in addition to the data of other MDI manufacturing companies.


    Also Read: Cipla moves against NPPA for price fixation of asthma drugs; DOP junks plea

    ashma breathing problem Cadila Healthcare Celing price Cipla Dept of pharma DOP Glenmark Healthcare inhalation Lupin Macleods Pharma National Pharmaceutical Pricing Authority NCLT NPPA pharma pharma news pharma news india respiratory diseases Tiomist Tiotropium Inhalation zydus Zydus Healthcare 

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      After Abbott, two more Stent makers seek withdrawal of New Gen Stents

      After Abbott, two more Stent makers seek withdrawal of New Gen Stents

      3.36% of about 82,600 drugs samples found to be substandard

      3.36% of about 82,600 drugs samples found to be substandard

      Johnson and Johnson must pay 4 million dollar in punitive damages in latest asbestos cancer trial

      Johnson and Johnson must pay 4 million dollar in punitive damages in latest asbestos cancer trial

      Sterling Biotech Bank Fraud: ED seize assets including business jet, ships, oil rings worth over Rs 9700 crore

      Sterling Biotech Bank Fraud: ED seize assets including business jet, ships, oil rings worth over Rs...

      Apollo medical centre in Oman granted hospital status

      Apollo medical centre in Oman granted hospital status

      Calcutta HC sets aside Centers decision for strategic sale of Bengal Chemicals

      Calcutta HC sets aside Center's decision for strategic sale of Bengal Chemicals

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      View All

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 27 May 2022 6:45 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
      verify here.

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
      X
      X